<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578951</url>
  </required_header>
  <id_info>
    <org_study_id>2018-41</org_study_id>
    <nct_id>NCT04578951</nct_id>
  </id_info>
  <brief_title>Measurement of the Quality of Life in Patients Operated With a Total Knee Prosthesis (TKA) From the FHK® Range.</brief_title>
  <official_title>Measurement of the Quality of Life in Patients Operated With a Total Knee Prosthesis (TKA) From the FHK® Range and Followed for 2 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FH ORTHO</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FH ORTHO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As part of Medical Devices CE marking regulatory process, an appropriate post-market clinical&#xD;
      follow-up (PMCF) is required. This PMCF study is in the framework of CE mark renew of FHK®&#xD;
      total knee prosthesis, it aims to answer specific questions related to safety and performance&#xD;
      of the device, when used in accordance with the approved instructions for use.&#xD;
&#xD;
      This study is based on a quality of life self-assessment from the preoperative to&#xD;
      postoperative phases and up to two years of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the quality of life in patients operated&#xD;
      with a FHK® total knee prosthesis up to 2 years of follow-up.&#xD;
&#xD;
      The secondary objectives are to evaluate the security and performance of the devices by&#xD;
      gathering complications, revision rate of the devices (survival analysis) and functional&#xD;
      score up to 2 years of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 28, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life EQ-5D-5L score</measure>
    <time_frame>14 days preoperative ; 70 days post-op, 177 days post-op, 357 days post-op, 717 days post-op</time_frame>
    <description>The primary outcome measures will be determined by the EQ-5D-5L score. The EQ-5D-5L score is a self-administered quality of life questionnaire by patients. The EQ-5D-5L consists of two parts, One part with a five-dimensional system and the last one is a visual analog scale graduated from 0 to 100. We will observe the evolution of this score according to the time frame.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>2 years post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of parameters describing pain, stability, knee mobility and patient autonomy</measure>
    <time_frame>From the preoperative visit to 2 years postoperative.</time_frame>
    <description>The secondary outcome measures will be determined by the KOOS-PS score, a patellar evaluation, and questions about physical abilities.&#xD;
The KOOS-PS score is a score used in the clinical evaluation of various knee pathologies.This score assesses both the long and medium term consequences of a knee injury. It contains 42 items in 5 separately scored subscales (pain, other symptoms, function in daily life, function in leisure and sports and quality of life related to the knee).&#xD;
The patellar evaluation is a questionnaire assessing the functional state of the knee with questions such as the level of pain in the anterior region of the knee, assessment of the strength of the quadriceps, the ability to rise from a chair.&#xD;
Physical abilities will be assessed with questions like the patient's walking distance, the ability to cycle, the ability to go shopping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>All complications will be gathered during intervention and up to 2 years postoperatively.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Knee Disease</condition>
  <arm_group>
    <arm_group_label>Patients receiving a prosthesis from the FHK® range</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FHK® total knee prosthesis</intervention_name>
    <description>FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.</description>
    <arm_group_label>Patients receiving a prosthesis from the FHK® range</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from participating hospitals will be enrolled as part of their clinical routine&#xD;
        care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject implanted with FHK® prosthesis in one of the following indication according to&#xD;
             the instructions for use: knee disorders; Aseptic condylar necrosis.&#xD;
&#xD;
          -  Subject who received an information form and is willing to participate in the study.&#xD;
&#xD;
          -  Adults subjects (≥18 years old).&#xD;
&#xD;
          -  Access to an internet connection allowing to complete the questionnaires on the online&#xD;
             platform&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications described in the instructions for use&#xD;
&#xD;
          -  Subject who is not able to express his/her non-opposition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>+33389818944</phone>
    <email>w.vandenberghe@groupe-fh.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux de Lannemezan</name>
      <address>
        <city>Lannemezan</city>
        <zip>65300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Maine</name>
      <address>
        <city>Laval</city>
        <zip>53 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pré</name>
      <address>
        <city>Le Mans</city>
        <zip>72018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Saint Jean de Luz</name>
      <address>
        <city>Saint-Jean-de-Luz</city>
        <zip>64500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médipôle Garonne</name>
      <address>
        <city>Toulouse</city>
        <zip>31 300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <keyword>Arthroplasty</keyword>
  <keyword>Replacement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

